Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated
12:51pm, Monday, 11'th Nov 2024
On Monday, AbbVie Inc ABBV stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials.
AbbVie Stock Sinks After Schizophrenia Drug Trials Disappoint
12:45pm, Monday, 11'th Nov 2024
Shares of AbbVie (ABBV) plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of Phase 2 clinical trials.
AbbVie: Emraclidine's Failure Eliminates An Important Growth Driver
11:49am, Monday, 11'th Nov 2024
Emraclidine's failure in phase 2 trials is a significant setback for AbbVie's neuroscience pipeline. This was a very surprising outcome after very strong phase 1b results and the success of competitor
AbbVie sheds $38bn in value after failing schizophrenia drug trials
11:03am, Monday, 11'th Nov 2024
Pharma giant AbbVie Inc has disclosed that Phase 2 trials of its emraclidine schizophrenia treatment have failed to meet their primary endpoint objectives. The treatment did not show a significant red
Bristol Myers Squibb's stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
11:00am, Monday, 11'th Nov 2024
Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug.
AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges
10:27am, Monday, 11'th Nov 2024
On Monday, AbbVie Inc ABBV stock is trading lower after it released data from its two Phase 2 EMPOWER trials of emraclidine for schizophrenia.
AbbVie Stock Falls Sharply as Schizophrenia Therapy Shows No ‘Significant' Improvement
09:25am, Monday, 11'th Nov 2024
Two trials of the company's experimental schizophrenia drug show no significant improvement in symptoms.
AbbVie's schizophrenia drug misses main goals of two trials
08:44am, Monday, 11'th Nov 2024
AbbVie said on Monday its experimental schizophrenia drug failed to meet the main goal of two mid-stage trials, sending its shares down more than 11% in premarket trading.
AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia
08:30am, Monday, 11'th Nov 2024
EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial NORTH CHICAGO, Ill. , No
3 Spectacular High-Yield Dividend Stocks to Buy in November
09:30am, Sunday, 10'th Nov 2024
High yields aren't a warning indicator with these three stocks.
My Favorite Dividend King to Buy in November
05:48am, Saturday, 09'th Nov 2024
This Dividend King truly wears the crown.
Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy?
10:36am, Friday, 08'th Nov 2024
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
Top 3 stocks to buy after Fed's 25-basis-point rate cut
10:06am, Friday, 08'th Nov 2024
US stocks remain resilient following the Federal Reserve's decision to lower its key interest rate by another 25 basis points on Thursday. According to the post-meeting statement: The Committee judges
2 Dividend Kings That Would Have Doubled Your Money in 5 Years
05:00am, Friday, 08'th Nov 2024
You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.
Dividend Watch: Three Companies Boosting Quarterly Payouts
05:50pm, Thursday, 07'th Nov 2024
Earnings season continues to move at a rapid pace, with many companies reporting daily. And recently, these three companies delivered news of higher dividend payouts.
